These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 11909815

  • 1. Matrix metalloproteinases: regulation and dysregulation in the failing heart.
    Spinale FG.
    Circ Res; 2002 Mar 22; 90(5):520-30. PubMed ID: 11909815
    [Abstract] [Full Text] [Related]

  • 2. Extracellular degradative pathways in myocardial remodeling and progression to heart failure.
    Spinale FG, Gunasinghe H, Sprunger PD, Baskin JM, Bradham WC.
    J Card Fail; 2002 Dec 22; 8(6 Suppl):S332-8. PubMed ID: 12555141
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Type-specific dysregulation of matrix metalloproteinases and their tissue inhibitors in end-stage heart failure patients: relationship between MMP-10 and LV remodelling.
    Wei Y, Cui C, Lainscak M, Zhang X, Li J, Huang J, Zhang H, Zheng Z, Hu S.
    J Cell Mol Med; 2011 Apr 22; 15(4):773-82. PubMed ID: 20219015
    [Abstract] [Full Text] [Related]

  • 9. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target.
    Spinale FG, Coker ML, Bond BR, Zellner JL.
    Cardiovasc Res; 2000 May 22; 46(2):225-38. PubMed ID: 10773226
    [Abstract] [Full Text] [Related]

  • 10. Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis.
    Fielitz J, Leuschner M, Zurbrügg HR, Hannack B, Pregla R, Hetzer R, Regitz-Zagrosek V.
    J Mol Med (Berl); 2004 Dec 22; 82(12):809-20. PubMed ID: 15558223
    [Abstract] [Full Text] [Related]

  • 11. Matrix metalloproteinases: pathways of induction by bioactive molecules.
    Tsuruda T, Costello-Boerrigter LC, Burnett JC.
    Heart Fail Rev; 2004 Jan 22; 9(1):53-61. PubMed ID: 14739768
    [Abstract] [Full Text] [Related]

  • 12. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure.
    Coker ML, Thomas CV, Clair MJ, Hendrick JW, Krombach RS, Galis ZS, Spinale FG.
    Am J Physiol; 1998 May 22; 274(5):H1516-23. PubMed ID: 9612358
    [Abstract] [Full Text] [Related]

  • 13. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling.
    Li YY, McTiernan CF, Feldman AM.
    Cardiovasc Res; 2000 May 22; 46(2):214-24. PubMed ID: 10773225
    [Abstract] [Full Text] [Related]

  • 14. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR.
    Circulation; 2006 May 02; 113(17):2089-96. PubMed ID: 16636176
    [Abstract] [Full Text] [Related]

  • 15. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation.
    Deschamps AM, Spinale FG.
    Cardiovasc Res; 2006 Feb 15; 69(3):666-76. PubMed ID: 16426590
    [Abstract] [Full Text] [Related]

  • 16. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat.
    Peterson JT, Li H, Dillon L, Bryant JW.
    Cardiovasc Res; 2000 May 15; 46(2):307-15. PubMed ID: 10773235
    [Abstract] [Full Text] [Related]

  • 17. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.
    Wilson EM, Gunasinghe HR, Coker ML, Sprunger P, Lee-Jackson D, Bozkurt B, Deswal A, Mann DL, Spinale FG.
    J Card Fail; 2002 Dec 15; 8(6):390-8. PubMed ID: 12528092
    [Abstract] [Full Text] [Related]

  • 18. Temporal changes in myocardial collagen, matrix metalloproteinases, and their tissue inhibitors in the left ventricular myocardium in experimental chronic mitral regurgitation in rodents.
    Corporan D, Onohara D, Hernandez-Merlo R, Sielicka A, Padala M.
    Am J Physiol Heart Circ Physiol; 2018 Nov 01; 315(5):H1269-H1278. PubMed ID: 30141979
    [Abstract] [Full Text] [Related]

  • 19. Extracellular matrix remodeling attenuated after experimental postinfarct left ventricular aneurysm repair.
    Hsu CP, Huang CY, Wang JS, Sun PC, Shih CC.
    Ann Thorac Surg; 2008 Oct 01; 86(4):1243-9. PubMed ID: 18805169
    [Abstract] [Full Text] [Related]

  • 20. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function.
    Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L.
    Circ Res; 1998 Mar 09; 82(4):482-95. PubMed ID: 9506709
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.